Hemera Biosciences Inc.
https://www.hemerabiosciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hemera Biosciences Inc.
Regenxbio: On The Cusp Of Becoming A Commercial Gene Therapy Player
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Start-Up Previews, July-August 2013
This Month's Profile Groups: Ocular Gene Therapy Sees The Light, features profiles of Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences; Smart Orthopedic Implants, feature profiles of OrthoData and Ortho-tag. Plus these Start-Ups Across Health Care: Colibri Heart Valve, Complix, Helmedix, Mapi Pharma, Mendor, Oligomerix, QuantuMDx, Silicon BioDevices, and Vigilant Biosciences.
Hemera Biosciences Inc.
Overactive membrane attack complex (MAC) in retinal host tissue may underlie the development of the drusen fatty deposits characteristic of dry age-related macular degeneration and the leaky vasculature in the wet form of AMD, which can eventually blot out central vision. Hemera Biosciences Inc. is developing a single-injection gene therapy with the potential to rebalance the complement system in the retina and induce lifetime protection against disease progression for both wet and dry forms of AMD.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice